0�8�1���Q�+^��ϴ�3}X����/X?�V.����S����O�������%�H�� <>>> If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Aranesp. 1 0 obj <> endobj … This protein may be reduced when you have kidney failure or use certain medications. Aranesp is a 165- amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3 chains. See below for a comprehensive list of adverse effects. x����$�*���޲'V��h ���������C�3 ��Z "��{��=�ϛ��������y���b)�������v]̿�we�we]Ϳnn:��C�/��_�������ׯ���"���_I�RDZ$���X\>���}M�]��U�k���!�L�h�������^�����oq��ׯ~Z�^����+���wb�0��������u� ���(g2H�#����m\y���Δ'>�2��W�,����,������Au7��*��of�'>V�ڷ��4�TT��C��L�>?��19����o��AL@i��,hkJ��ْh(?���(���{Bq����[I�~�$�H9x��@��K3��D�g�cY�������q�?�`/���.fg�����������Ϻ#���cC$�� _!3_��H��+Q7b�o stream Common side effects of Aranesp include: hypertension and peripheral edema. �-��5R��8�RH� � �h�ׯn YW�K#S=��A���1��}���. When fewer red blood cells are produced, you can develop a … %���� Aranespä is an erythropoiesis stimulating protein closely related to erythropoietin that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating protein that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Aranesp 500 mcg/mL (in polysorbate) injection syringe. 2.25 mcg/kg SC qWeek OR 500 mcg SC q3Weeks . Aranesp ® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chemotherapy that will be used for at least two months after starting Aranesp ®. If Hgb increases . b �%=/ʶ��~k,Y{糳�[�:yS�X��b�X�B]���7�ͤƆ��b���ERY�[�݃\̗�bF*��^�MѮ����m�^��-�l�MڻG�E|6rh <> Common side effects of Aranesp include: headache, body aches, color colorless shape No data. endobj Aranesp (darbepoetin alfa) is a member of the recombinant human erythropoietins drug class and is commonly used for Anemia Associated with Chronic Renal Failure and Anemia - Chemotherapy Induced. Initial Approval Criteria1-16 Coverage is provided in the following condition(s): 3 0 obj Other side effects include: congestive heart failure and hypervolemia. <>/ExtGState<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> What is Aranesp? 1 The 2 … 2 0 obj The IV route of administration … imprint No data. %PDF-1.5 Aranespä is a 165-amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3. Aranesp ® is also available in 150, 200, 300, and 500 mcg dose strengths. Aranespä is a 165-amino acid protein that differs from recombinant human erythropoietin in containing 5 N-linked oligosaccharide chains, whereas recombinant human erythropoietin contains 3. Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent, or ESA, used to treat anemia (a lack of red blood cells in the body) in people with long-term serious kidney disease (chronic renal failure) and people receiving chemotherapy for some types of cancer. Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. This medicine is a colorless, solution ‹ Back to Gallery. Aranesp® (darbepoetin alfa) injection is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney … Aranesp (darbepoetin alfa) is a man-made form of a protein that helps your body produce red blood cells. 4 0 obj 500 mcg: 1 vial or prefilled syringe up to every 21 days B. Max Units (per dose and over time) [HCPCS Unit]: MDS or MPN (J0881 only): 900 billable units every 21 days All other indications: 600 billable units every 21 days III. DESCRIPTION. endobj Aranesp ® is available in single-dose vials and prefilled syringes, except the 10, 150, and 500 mcg dose strengths, which are available only as prefilled syringes. The recommended starting dose is 0.45 mcg/kg intravenously or subcutaneously as a weekly injection or 0.75 mcg/kg once every 2 weeks as appropriate. �F��~,��뢡-_��PU�q_�b�O��$ĂTU��EՕ9IN��%����zmL���f��F�dk��*�V�Պu�ȗ�# �_-:����m��ⱄ��.�vq�g�J�4v���u?~B��O�uu-Rt�!y1������E���P�t�t�Џ�;�2��EB��� ���&Ü7yF��}��/�����cp'l3v���e�����J���z6�&�Q��ďy�B�}���r���'�!�.6�0R�i����*,*��߆ Initiate Aranesp treatment when the hemoglobin level is less than 10 g/dL.